Quantcast

Radiation Oncology Experts From 16 Countries Attend Technical University of Munich’s International Conference on TomoTherapy

October 29, 2008

TomoTherapy Incorporated (NASDAQ: TOMO) announced today that Technical University of Munich, Germany, recently welcomed 175 radiation oncology experts from 16 countries to the ‘International Conference on the Clinical Use of TomoTherapy’. The two-day event featured 35 technical talks from doctors and physicists. Presentations covered the multiple cancer types clinicians are treating with CT-guided, helical TomoTherapy(SM) and treatment protocols that show promise in gaining improved outcomes for patients.

“We were extremely pleased to host this exciting scientific meeting to explore the clinical use of TomoTherapy,” said Prof. Michael Molls, M.D., chairman of Radiation Oncology, Klinikum Rechts der Isar, Technical University of Munich. “Our clinic has used TomoTherapy for the last 2 years in a project funded by the German Oncology research foundation. This new technology, which combines CT imaging with a linear accelerator in one device, allows us to treat patients with a higher accuracy and to better shape dose distributions to target tumour volumes.”

Notable conference presentations included:

— Dr. Patrick Kupelian, director of Clinical Research for Radiation Oncology at MD Anderson Cancer Center Orlando, Florida on TomoTherapy for prostate cancer; and

— Prof. Guy Storme, M.D., Ph.D., director of the Oncologic Center at UZ Brussel, Brussels, Belgium on the use of TomoTherapy for the treatment of head and neck tumours;

“The gathered international clinicians enjoyed presentations covering many of the clinical possibilities for TomoTherapy,” said Dr. Kupelian. “Evidenced in many presentations is the need for volumetric daily image guidance such as that provided on the TomoTherapy Hi-Art(R) treatment system. It is important to continue such meetings to allow sharing of experience with the goal to deliver improved outcomes for our patients.”

Prof. Storme added, “Meetings like this help us understand the range of possibilities with a platform like TomoTherapy and highlight the need for clinical Phase 3 studies to make most use of this technology which seems to have a beneficial effect for patients in reducing side effects.”

Thomas ‘Rock’ Mackie, Ph.D., TomoTherapy co-founder and chairman of the board, discussed the experience of taking TomoTherapy from concept to clinical routine and thanked Technical University of Munich for organizing a successful conference.

“I am excited to see so many respected members of the international radiation oncology community gather to present the wonderful work they are doing with TomoTherapy,” said Mackie. “It is a great opportunity for us to see the way the potential of this platform is being explored and how future developments will extend the possibilities.”

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy(R) Hi-Art(R) treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi-Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

(C)2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi-Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.




comments powered by Disqus